Stockreport

Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]

Amylyx Pharmaceuticals, Inc.  (AMLX) 
PDF Cost of Sales: $800,000 related to discontinued commercial sales. Research and Development Expenses: $21.2 million for Q3 2024, down from $30 million in Q3 2023. Se [Read more]